For US Residents
For US Residents
You are about to leave OurWayForward.com.
You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content.
Our Mission
Our Way Forward is a call-to-action that encourages people living with gynecologic cancers, such as endometrial and ovarian cancer, their loved ones, and healthcare professionals to rethink how they talk about these cancers. The program provides ways to learn from each other’s cancer experiences and to help navigate the physical and emotional challenges that these diseases may bring.
Our Way Forward was created by the community, for the community. In 2017, GSK conducted a national survey of patients and physicians treating ovarian cancer. Along with input from advocacy organizations, these collective community insights led to the creation of Our Way Forward, a community-driven supportive resource for ovarian cancer. Since then, Our Way Forward has expanded to include resources and information for endometrial cancer.
GSK is continually seeking insights from the gynecologic community to evolve Our Way Forward as an educational resource.
Your Cancer Is Our Challenge (YCIOC)
YCIOC is a global, multi-year integrated initiative that aims to uncover and address gaps and barriers associated with gynecologic cancers with a goal to create solutions to drive progress–beyond treatment.
GSK commissioned The Harris Poll to conduct a quantitative online survey among 818 multinational gynecologic cancer patients. Of that, 102 participants were from the United States. Key survey findings revealed unmet needs among these patients, including:
Barriers to care
Gaps in information and understanding
Emotional burden of treatment and care
Low utilization of patient support
YCIOC Harris Survey Details
YCIOC was a multinational online survey conducted from March 13 - May 13, 2024 by the Harris Poll on behalf of GSK of 818 adult women ages 18+ who were diagnosed with ovarian, uterine/endometrial/womb, cervical, vulvar, and/or vaginal cancer. Of that, 102 participants were from the United States. The results of this survey reflect various individual experiences and may not align with your own.
Key U.S. Findings from the Survey
U.S. patients wanted more information about: the impact of treatment on overall health (66%), signs and symptoms (56%), various available treatment options (54%), risk factors for developing gynecologic cancer (51%), and what to expect during the treatment journey (50%).
Nearly 2 in 3 patients (63%) were not taking advantage of patient support resources like participating in a support group
More than 2 in 3 patients surveyed (70%) were not typically relying on patient support resources like support groups or patient associations for information on gynecologic cancers
Around 1 in 4 patients experienced feelings of being to blame for their cancer because they didn’t address their symptoms or see a healthcare professional soon enough (28%) or because they had unprotected sex (16%), embarrassment about having gynecologic cancer because of the stigmas that exist around gynecologic cancers (25%), or general embarrassment about their symptoms (16%)
GSK is grateful to all of the community members who have lent their voices, expertise, and insights to develop this disease education resource, Our Way Forward. GSK is passionate about supporting the gynecologic cancer community.
Explore the GSK Help Center website to find customer service support and contact information.